Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy

Research output: Contribution to journalJournal articlepeer-review


  1. Collaboration in colorectal surgical research

    Research output: Contribution to journalJournal articlepeer-review

  2. Predicting life with a permanent end colostomy: A prospective study on function, bother and acceptance

    Research output: Contribution to journalJournal articlepeer-review

  • J Z Musoro
  • S C Sodergren
  • C Coens
  • A Pochesci
  • M Terada
  • M T King
  • M A G Sprangers
  • M Groenvold
  • K Cocks
  • G Velikova
  • H-H Flechtner
  • A Bottomley
View graph of relations

AIM: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses the health-related quality of life of patients in cancer trials. There are currently no minimally important difference (MID) guidelines for the EORTC QLQ-C30 for colorectal cancer (CRC). This study aims to estimate MIDs for the EORTC QLQ-C30 scales in patients with advanced CRC treated with chemotherapy and enrolled in clinical trials.

METHOD: The data were obtained from three published EORTC trials that treated CRC patients using chemotherapy. Potential anchors were selected from clinical variables based on their correlation with EORTC QLQ-C30 scales. Anchor-based MIDs for within-group change and between-group change were estimated via the mean change method and linear regression, respectively, and summarized using weighted correlation. Distribution-based MIDs were also examined.

RESULTS: Anchor-based MIDs were determined for deterioration in 8 of the 14 EORTC QLQ-C30 scales and in 9 scales for improvement, and varied by scale, direction of change and anchor. MIDs for improvement (deterioration) ranged from 6 to 18 (-11 to -5) points for within-group change and 5 to 15 (-10 to -4) for between-group change. Summarized MIDs (in absolute values) per scale mostly ranged from 5 to 10 points.

CONCLUSIONS: These findings have clinical relevance for the interpretation of treatment efficacy and the design of clinical trials by informing sample size requirements.

Original languageEnglish
JournalColorectal Disease
Issue number12
Pages (from-to)2278-2287
Number of pages10
Publication statusPublished - Dec 2020

Bibliographical note

Publisher Copyright:
© 2020 The Association of Coloproctology of Great Britain and Ireland

Copyright 2020 Elsevier B.V., All rights reserved.

    Research areas

  • Advanced colorectal cancer, EORTC QLQ-C30, clinical anchors, health-related quality of life (HRQOL), minimally important difference (MID)

ID: 61353295